References
- [1]
- J. Storopoli. Bayesian Statistics with Julia and Turing (2021).
- [2]
- M. M. Hutmacher and K. G. Kowalski. Covariate selection in pharmacometric analyses: a review of methods. British journal of clinical pharmacology 79, 132–147 (2015).
- [3]
- J. S. Owen and J. Fiedler-Kelly. Introduction to population pharmacokinetic/pharmacodynamic analysis with nonlinear mixed effects models (John Wiley & Sons, 2014).
- [4]
- (Editor). Implementing Variable Selection Techniques in Regression (American Educational Research Association, ERIC, Boston, MA, USA, 1990).
- [5]
- P. McCullagh and J. Nelder. Generalized Linear Models, Second Edition. Chapman and Hall/CRC Monographs on Statistics and Applied Probability Series (Chapman & Hall, 1989).
- [6]
- A. Hald. Maximum likelihood estimation of the parameters of a normal distribution which is truncated at a known point. Scandinavian Actuarial Journal 1949, 119–134 (1949).
- [7]
- S. L. Beal. Ways to fit a PK model with some data below the quantification limit. Journal of pharmacokinetics and pharmacodynamics 28, 481–504 (2001).
- [8]
- H. White. Maximum Likelihood Estimation of Misspecified Models. Econometrica 50, 1–25 (1982).
- [9]
- B. Efron. Bootstrap Methods: Another Look at the Jackknife. The Annals of Statistics 7, 1–26 (1979).
- [10]
- A.-G. Dosne, M. Bergstrand, K. Harling and M. O. Karlsson. Improving the estimation of parameter uncertainty distributions in nonlinear mixed effects models using sampling importance resampling. Journal of pharmacokinetics and pharmacodynamics 43, 583–596 (2016).
- [11]
- S. D. Patterson and B. Jones. Bioequivalence and statistics in clinical pharmacology (CRC Press, 2017).
- [12]
- S.-C. Chow and J.-P. Liu. Design and analysis of bioavailability and bioequivalence studies (CRC press, 2008).
- [13]
- X. Y. Lawrence and B. V. Li. FDA bioequivalence standards. Vol. 13 (Springer, 2014).
- [14]
- (Editor). On the error of the Laplace approximation when lags and duration parameters have between-subject variation. Vol. 31 (Population Approach Group Europe, A Coruña, Spain, Jun 2023). Abstract 10625.
- [15]
- R. Savic, D. Jonker, T. Kerbusch and M. Karlsson. Evaluation of a transit compartment model versus a lag time model for describing drug absorption delay. Population Approach Group Europe: Uppsala, Sweden, 513 (2004).
- [16]
- D. Hartmann, D. Gysel, U. Dubach and I. Forgo. Pharmacokinetic modelling of the plasma concentration-time profile of the vitamin retinyl palmitate following intramuscular administration. Biopharmaceutics & drug disposition 11, 689–700 (1990).
- [17]
- R. M. Savic, D. M. Jonker, T. Kerbusch and M. O. Karlsson. Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. Journal of pharmacokinetics and pharmacodynamics 34, 711–726 (2007).